Asthma Tied to Increased Risk of Chronic Migraines

This article originally appeared here.
Share this content:
Asthma Tied to Increased Risk of Chronic Migraines
Asthma Tied to Increased Risk of Chronic Migraines

FRIDAY, Dec. 11, 2015 (HealthDay News) -- People with asthma may be more than twice as likely to develop chronic migraines as those without asthma, according to a study published online Nov. 19 in Headache.

The research included 4,446 Americans. At the start of the study in 2008, the study volunteers had fewer than 15 migraines a month. One year later, the researchers looked to see how many had chronic migraine, defined as 15 or more migraines a month.

More than 5 percent of people with asthma developed chronic migraine, compared to 2.5 percent of those without. The lead author Vincent Martin, M.D., a professor of medicine and co-director of the Headache and Facial Pain Program at the University of Cincinnati, said in a university news release that having asthma was an even stronger predictor of chronic migraines than depression.

"Migraine and asthma are disorders that involve inflammation and activation of smooth muscle either in blood vessels or in the airways," study coauthor Richard Lipton, M.D., director of Montefiore Headache Center in New York City, said in the news release. "Therefore, asthma-related inflammation may lead to migraine progression."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths